Check out the companies making headlines after the bell Tuesday:

Shares of Juno Therapeutics soared close to 40 percent in the extended session. Dow Jones reported biotechnology giant Celgene was in talks to buy the cancer bio-pharmaceutical company. Shares of Celgene edged down 1.7 percent.